Potential of chimeric antigen receptor (CAR) T cell immunotherapy in systemic lupus erythematosus (SLE) - PubMed
7 hours ago
- #CAR T-cell therapy
- #Autoimmune disease treatment
- #Systemic lupus erythematosus
- CAR T-cell therapy shows potential as a novel treatment for systemic lupus erythematosus (SLE), offering more effective and potentially curative options.
- The treatment landscape for SLE is transforming as of 2025, driven by innovative immunotherapies that target autoimmune dysregulation.
- Research on CAR T-cell therapy in SLE explores mechanisms, challenges, and future directions, with targets like BCMA, CD19, and CD22 being investigated.
- SLE is a chronic autoimmune disease with multiorgan inflammation, where conventional therapies often face resistance and significant side effects.